About Fermiscan Limited

Fermiscan is working to develop a world-first innovative test for the detection of breast cancer using hair. The breakthrough technology that underpins the Fermiscan™ Test is the discovery by an Australian scientist that breast cancer can potentially be detected by synchrotron x-ray diffraction of hair. The test is non-invasive and suitable for women from as early as 20 years of age. It may provide early detection of breast cancer thus assist in early treatment. Early detection benefits range from increased survival, increased treatment options and improved quality of life. The Fermiscan™ Test is in trial and not yet available commercially.

Ethics

Fermiscan has established an ethics committee to review the design and conduct of projects involving human research. Fermiscan is committed to ensuring that its projects are in keeping with the Commonwealth of Australia’s National Statement on Ethical Conduct Involving Humans.

The National Statement promotes ethically good human research which ensures that research participants are treated with due respect and protection. It provides guidelines for institutions, researchers and review bodies to follow in order to identify ethical issues in the design, review and conduct of human research and ensure they are dealt with appropriately.

The Fermiscan Human Research Ethics Committee is registered with the National Health and Medical Research Council’s Australian Health Ethics Committee.

Details of its membership, terms of reference and point of contact can be found below.

PDF downloads

 

PDF Terms of Reference

PDF FHREC Membership

 

Click on PDF iconsPDF to download.

Contact details


If you require any further information about the Fermiscan Human Research Ethics Committee please contact the Fermiscan Human Research Ethics Committee Executive Officer.

Executive Officer
 

Gloria Rodgers

Address
  

Fermiscan Limited
 

Level 5, 48 Hunter Street, Sydney 2000
Email
  

ethics@fermiscan.com.au
Phone
  

(02) 9245 4460
Fax
  

(02) 9223 9622